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Abstract Recently, we developed avalidated computerprogrambased onpolychotomouslogistic regression analysis
usingbronchoalveolarlavage £uid (BALF) results to distinguishbetweenthethreemostcommoninterstitiallungdiseases
(ILD): sarcoidosis, idiopathicpulmonary ¢brosis (IPF) andextrinsic allergic alveolitis (EAA) ordrug-inducedpneumonitis.
One of the limitations of this programwas that it was not useful in discriminating between infectious disorders andnon-
infectious disorders.Therefore, we added BALF samples obtained frompatientswith a con¢rmed bacterial pulmonary
infection based on culture results 5104 cfuml71 (group I: n=31) to the study population mentioned above (group II:
n=272). Notably, just one variable, i.e. the percentage of polymorphonuclear neutrophils, allowed us to distinguish
betweeninfectious andnon-infectious disorders.The agreementof predictedwiththe actual diagnostic groupmember-
ship was 99?67% (groups I and II). Additionally,91?2% of the cases with ILD were correctly classi¢ed. In conclusion, this
updated Windows version 2000 of the validated computer program provides a very reliable prediction of the correct
diagnosis for an arbitrarypatientwith suspectedpneumonia or with ILD given information obtained from BALFanalysis
results, and is thoughtto improve the diagnostic powerof BALFanalysis.c 2001Harcourt Publishers Ltd
doi:10.1053/rmed.2001.1153, available online athttp://www.idealibrary.comon
Keywords bronchoalveolar lavage (BAL); extrinsic allergic alveolitis (EAA); hypersensitivity pneumonitis (HP); idiopathic
pulmonary ¢brosis (IPF); pulmonary infection; interstitial lung disease (ILD); sarcoidosis.INTRODUCTION
Di¡use interstitial lungdisease (DILD) poses a signi¢cant
challenge for the clinician because the aetiology is often
unknown (1,2).To establish the diagnosis a thorough his-
tory is essential as itmay identify a potential aetiological
factor.Manydiagnostic procedures are useful, in particu-
lar a high-resolution computed tomography (HRCT)
scan and a bronchoalveolar lavage (BAL) (1). A BAL
readily explores large areas of the alveolar compartment
providing cells as well as non-cellular constituents from
the lower respiratory tract. Therefore, BAL represents
an additional tool in assessing diseases involving the lung
parenchyma. After the introduction as a research tool,Received 5 December 2000 and accepted in revised form16May 2001
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Box 5800, 6202 AZMaastricht,The Netherlands.Fax: +31433875051;
E-mail: mdr@slon.azm.nlBALhasbeen appreciatedextensively for clinical applica-
tions (3,4). When applied according to standardized
protocols and considered in the context of other
information from conventional ancillary diagnostic tests,
BAL appears to be useful in the diagnosis of DILD, pneu-
monia (especially opportunistic infections) and some-
times malignancies with pulmonary localization (3^7).
Careful analysis of the cellular BAL £uid (BALF) pro¢le,
together with a thorough evaluation of clinical andradiol-
ogical features, allows prediction of the underlying dis-
order or ruling out a diagnosis with a high sensitivity and
speci¢city (4). In this respect, it has the advantage of
avoiding more invasive diagnostic procedures, such as
tissue biopsies.
If the clinician decides that a BAL might be helpful to
provide diagnostic material it is mandatory to have reli-
able diagnostic criteria.Therefore, the interpretation of
cellular BALF analysis results has to be standardized to
improve the diagnostic power. Previously, we studied
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ing from either sarcoidosis, extrinsic allergic alveolitis
(EAA) or idiopathic pulmonary ¢brosis (IPF). A logistic
regression equationwas constructedusing several BALF
parameters as variables to provide the most likely
diagnosis (8,9). The diagnosis had been established
independently of the BALF-analysis results.The variables
used to discriminate among these patient groups were
the yield of recovered BALF, total cell count, and
percentages of alveolar macrophages, lymphocytes,
neutrophils and eosinophils. This equation appeared to
be accurate in 91?2% of the cases. To date, inclusion of
the BALF CD4/CD8 ratio in the analysis did not result
in better prediction. However, one of the limitations of
this logistic regression equationwas, among others, that
it was not useful to distinguish disorders of infectious
aetiology and non-infectious aetiology (8,9). Furthermore,
Jacobs et al. demonstrated the value of BALF cytological
¢ndings for the diagnosis of non-infectious conditions in
patients with suspected pneumonia (7). Similarly Cobben
et al. found that only one cellular variable, the number of
polymorphonuclear neutrophils (PMNs), appeared to dis-
tinguish between infectious and non-infectious disorders
(10). Moreover, the ¢rst DOS edition of the computer
model (9) appeared not to bemillennium-proof.
Therefore, the aim of this study was to provide an up-
dated clinical useful computer program (a millennium-
proof Windows version) to distinguish the three most
common above-mentioned ILD, as well as to distinguish
those non-infectious disorders from bacterial infectious
pulmonary disorders using just one simple software pro-
gram.
MATERIALANDMETHODS
General experimental design
Group I consisted of the initial BALF specimens of pa-
tients with a con¢rmed nosocomial bacterial pulmonary
infection (n=33) selected fromBALF analyses performed
during a 2-year period in the University Hospital Maas-
tricht, The Netherlands, as previously reported (10). All
these patients were suspected of having pneumonia as
de¢nedby clinical and radiological criteriawith new, per-
sistent or progressive in¢ltrate on the chest radiograph
(11).The positive culture results of the BALF samples ob-
tained from group I were: Haemophilus in£uenzae (n=7),
Staphylococcus aureus (n=6), Pseudomonas aeruginosa
(n=6),Escherichia coli (n=2),Proteusmirabilis (n=2), Strepto-
coccus pneumoniae (n=1), Klebsiella pneumoniae (n=1),
Klebsiella oxytoca (n=1),Citrobacter diversus (n=1), Pseudo-
monas aeruginosa and Proteus mirabilis (n=1), Staphylococ-
cus aureus and Haemophilus in£uenzae (n=1),
Streptococcus pneumoniae and Neisseria meningitidis
(n=1), Escherichia coli and Klebsiella oxytoca (n=1),Escherichia coli and Haemophilus in£uenzae (n=1), Proteus
mirabilis andHaemophilus in£uenzae (n=1).
Group II consisted of the initial BALF specimens ob-
tained from patients with sarcoidosis, EAA or IPF
(n=272) selected from BALF analyses performed in a10-
year period at the Sint Antonius Hospital, Nieuwegein,
The Netherlands (8). As previously reported (8,9), a di-
agnosis of sarcoidosiswas histologically proven.The diag-
nosis of EAA was based on clinical information, chest
radiography, pulmonary function tests, the presence of
precipitines in peripheral blood and disappearance of
symptoms after avoidance of the causative antigen or, in
some cases, after a short treatmentwith corticosteroids.
The diagnosis of IPF was histological proven. Alveolitis
demonstrated an in¢ltration of mononuclear cells,
interstitial pneumonitis and/or derangement of parench-
ymal structures, i.e. ¢brosis (8,9).
MEASUREMENTS
BALwasperformedduring ¢breoptic bronchoscopy.The
procedure was reported previously (8^10). Brie£y, BAL
was performed by standardized washing of the involved
lobe (group I), or the middle or lingula lobe (group II)
with four aliquots of 50ml sterile saline (0?9% NaCl) at
378C after premedication (0?5mg intramuscular atropine
and sometimes 5^10mg diazepam orally) and local
anaesthesia of the larynx and bronchial tree (lidocaine
0?5%). In group I, if the patient was intubated, the
bronchoscopewas introduced through the tube.
Upon arrival in the laboratory, the recovered volume
of the BALF was recorded.The ¢rst fraction (bronchial
fraction)was discardedand theremaining fractions were
pooled. After mixing, the BALF was split into two
portions. Portion one was immediately sent to the de-
partmentof clinical chemistry andportion twowasused
for cytological andmicrobiological analysis.The total cell
count was performed in a Fuº chs^Rosenthal haemo-
cytometer chamber. Cytocentrifugation was done with
the Shandon Cytospin 3 apparatus (Shandon Scienti¢c
Ltd, Astmoor, U.K.), using the following conditions:
speed 650 rpm, time: 10min and acceleration rate: low.
In order to obtain monolayer preparations, the number
of drops per preparation was adjusted according to the
total cell count.Thepreparationswere air-dried and sub-
sequently stained according to the May^Gruº nwald^
Giemsa (MGG) and Gram-staining methods. At least
500 nucleated cells were counted. In group II infection
was excluded based on culture results of BALF. In group
I the number of cells containing intracellular organisms
was expressed as a percentage of all nucleated cells
counted (12). BALF samples containing excessive
amounts of red blood cells, squamous epithelial and/or
ciliated cells, background debris or damaged nucleated
cells were excluded from analysis, as well as BALF
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tuberculosis. Quantitative bacterial cultures were per-
formed on appropriatemedia incubatedboth aerobically
and anaerobically. Mycobacterial and fungal cultures
were performed on all BALF samples.Of infectious ae-
tiology, BALF samples were de¢ned as those samples
with a quantitative culture yielding5104 colony forming
units (cfu)m171.
STATISTICALEVALUATION
Logistic regression analysis was used to discriminate
group I [n=31; subjects with a pulmonary infection (10)]
from group II [n=272; subjects with one of the three
most common ILD mentioned above (8,9)]. In an earlier
study a logistic regression model for distinguishing the
three common ILD from each other (sarcoidosis, IPF
and EAA) was developed, mainly using variables derived
from BALF.This previously developed logistic regression
model had also been tested (validated) in another data
set (9).
Rather than considering group I as a fourth disease,
and redeveloping and revalidating a new logistic regres-
sion model for simultaneously distinguishing four lung
diseases from each other, a stepwise strategy was cho-
sen. In the ¢rst step a logistic regressionmodel (to be de-
veloped in this study) was used for distinguishing BALF
samples obtained from patients with a pulmonary infec-
tion (group I) from BALF of patients with ILD of non-
infectious origin (group II). If this distinction turned out
to be in favour of non-infectious lung disease, in the
second step, the already validated logistic regression
model could be used for distinguishing between the
three non-infectious ILD: sarcoidosis, IPF and EAA (9).
RESULTS
The characteristics and BALF analysis results of group I
(10) and group II (8,9) have been reported previously.
These data are summarized inTable1. In contrast towhat
was found in the sub-populations of group II, in group I
no signi¢cant di¡erence was demonstrated between
smokers and non-smokers (10). The explanatory
variables derived from BALF used in this study for
distinguishing pulmonary diseases of infectious and non-
infectious origin were: yield or recovery [(out/in)6
100% of the BALF], total cell count (TCC)6104ml71,
percentages of eosinophils, polymorphonuclear neutro-
phils (PMNs), lymphocytes and alveolar macrophages,
respectively. These variables were non-missing for 31
subjects with a pulmonary disorder of a bacterial
infectious origin (group I) and 272 subjects with non-
infectious ILD (group II). Univariate testing (using the
Mann^Whitney test) showed signi¢cant di¡erences
between both groups of patients for each of thesevariables separately (P50?0001). The most signi¢cant
one appeared to be the percentage of PMNs
(P50?00001). No other BALF variable or demographic
characteristic of the population studied was included in
the discriminant analysis. If this variable was introduced
in a logistic regression model, then 271 of the 272 BALF
samples obtained from subjectswithout an infection and
all 31BALF samples obtained frompatientswith abacter-
ial pulmonary infection were predicted as such. All
remaining variables were far from signi¢cant when
added to the model containing the percentage of PMNs
(P-value ranging from 0?42 to 0?93; likelihood ratio tests).
The estimated coe⁄cient of the percentage PMNs
equals 0?1498 (log odds ratio; SE=0?0517; P50?0001 likeli-
hood ratio test). This means that with each per cent
point increase in the PMN percentage, the odds of infec-
tion is multiplied by an odds ratio of e0?1498=1?16
(odds=the probability of infection divided by 17the
probability of infection).
A PMN percentage exceeding the cut-o¡ value of 65%
yields a positive predictive value of 31true infections out
of 32 predicted (96?9%) and a negativepredictivevalue of
271 true non-infections out of 271 predicted (100%).The
sensitivity and speci¢city are, respectively, 100% (31
correctly predicted out of 31 true infections) and 99?6%
(271correctly predicted out of 272 true non-infections).
Additionally, the constructed logistic regression equa-
tion using several BALF parameters as variables to pro-
vide the most likely diagnosis (8,9) revealed a correct
classi¢cation in 91?2% of the cases in the learning set
and 94?5% in a test set (population patients su¡ering
from ILD in another hospital, n=128) used to validate
the program, respectively (9).
DISCUSSION
This studydemonstrated that the cellular pro¢le ofBALF
samples of bacterial infectious aetiology appeared to be
signi¢cantly di¡erent from samples of non-infectious
aetiology. Notably, just one variable, e.g. the percentage
of PMNs, allowed to distinguish between bacterial infec-
tions and non-infectious disorders. The agreement of
predicted with the actual diagnostic group membership
was 99?67% for this distinction. The previous equation
(8) has notchanged at all, but a preliminary analysis using
a single cut-o¡ value for the percentage PMNs (65%)was
performed to rule out infection (before themultivariate
equation was applied to diagnose the type of ILD). The
reason for having chosen this conservative and theoreti-
cally sub-optimal strategy is that not all variables used
for discrimination within group II were available in all
cases of group I (e.g. smoking). Considering group I a
fourth disease would then have invalidated the predic-
tion rules used for discriminating the three diseases
within group II. Another reason is that with only two
centres there is the risk that the discriminatory power
TABLE 1. Bronchoalveolarlavage £uidvariables fromthe studied subpopulationsusedinthepolychotomousregressionmodel
Studygroups (n) Yield (%) TCC6104ml71 AMs* PMNs* Lym* Eos*
Sar (Nsm) (145) 55?6+1?0 18?9+10?0 63?2+1?5 1?7+0?4 34?5+1?5 0?55+0?1
(20?0785?0) (3?6763?0) (18?1798?0) (0764?0) (0?9780?2) (075?0)
Sar (Sm) (45) 56?6+1?6 31?5+23?9 74?9+2?5 1?2+0?2 23?0+1?8 0?7+0?2
(22?5782?5) (6?47167?1) (33?0798?8) (074?8) (0767?0) (075?1)
EEA (Nsm) (34) 46?4+1?8 41?7+25?6 38?2+1?5 4?3+0?6 58?1+2?6 2?6+0?5
(25?0767?5) (3?47110?9) (5?2775?1) (0?2712?4) (14?6783?2) (0714?3)
EAA (Sm) (4) 43?4+4?6 54?6+34?6 57?3+5?6 5?8+1?2 40?8+7?5 3?3+2?3
(31?0752?5) (30?07105?7) (41?1772?8) (2?678?0) (19?8753?9) (0?5710?3)
IPF (Nsm) (27) 42?6+2?4 24?2+29?5 67?8+3?7 11?7+1?9 13?8+3?0 6?4+1?8
(12?5765?0) (5?57168?8) (44?8791?7) (0?9739?5) (0?9743?6) (0738?6)
IPF (Sm) (17) 46?1+4?2 51?9+25?2 63?3+8?5 18?9+8?9 10?2+2?7 7?6+2?8
(30?0770?0) (5?57168?8) (8?1788?8) (0?2789?6) (0?1720?0) (0?3748?2)
Infectious (31) 28?9+5?1 329?1+84?8 7?0+1?3 90?5+1?5 1?9+0?5 0?04+0?3
(Nsm+Sm) (7?5767?5) (772432) (0725?0) (68?8799?8) (0710?8) (070?8)
Data are expressed asmean+standard errorofthemean(SEM), withrange inparentheses.TCC: total cell count; AMs: alveo-
larmacrophages;PMNs: polymorphonuclear neutrophils;Lym: lymphocytes;Eos: eosinophils; Sar: sarcoidosis;EAA: extrinsic
allergic alveolitis; IPF: idiopathic pulmonary ¢brosis;Nsm: non-smokers; Sm: smokers
*Percentages of the total cell count.
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potential accuracybias between the laboratories of both
centres. Itwouldnotberight to sacri¢ce the earlier well-
validatedmodel in group II for this. Additionally,91?2% of
the caseswithin thenon-infectious groupwere correctly
classi¢ed with respect to their actual ILD
diagnosis (sarcoidosis, EAAor IPF) (8,9).Note that there
is no predominant cell type present in BALF, e.g. the
percentage of lymphocytes or the CD4/CD8 ratio, but
a combination of features, an elevated total cell count,
predominantly lymphocytes together with a nearly
normal percentage of eosinophils and PMNs and the
lack of plasma cells appeared to be important to
distinguish the most likely diagnosis of sarcoidosis in
certain cases from an infectious aetiology, i.e. EAA and
IPF, respectively.
In addition to their defensive role,PMNshavebeen im-
plicatedmore recently in injurious processes associated
with both acute and chronic pulmonary diseases (10,13).
In the normal lung, PMNs are commonly absent. How-
ever, in certain conditions, PMNs can accumulate within
the lung structures (10,13,14). Until now little attention
has been paid to the usefulness of this particular cell in
distinguishing BALF samples of infectious aetiology from
non-infectious aetiology. Previously, Kirtland et al. (15)
found that less than 50% PMNs in BALF had a100%nega-
tive predictive value for pneumonia.Marquette et al. (16)
also found increased PMNs in patients with pneumonia
(87+13%) in comparison to patients without pneumonia
(49+32%). In line with this, an increased number of
PMNswas found in BALF samples of infectious aetiology
(group I) compared to the group of non-infectiousaetiology (group II) (10). The percentage of PMNs
demonstrated a high speci¢city in this study. However,
we realize that one of the important limitations of the
present analysis is that it does not allow other pulmon-
ary disorders with a neutrophil excess in BALF to be dis-
tinguished such as acute respiratory distress syndrome
(ARDS) (17^20), acute interstitial pneumonia (AIP) (21),
severe IPF or Sweet’s syndromewith pulmonary in¢ltra-
tion associated with myelodysplasia (6) from active
bacterial pulmonary infections. Exclusion of infectious
pneumonias is of great clinical importance as these dis-
orders require a di¡erent therapeutic approach. To-
gether with the clinical history and other investigations,
identifying numerous haemosiderin-laden marcrophages
may be indicative of acute lung injury di¡use alveolar
damage (DAD), associated with alveolar haemorrhage
syndromes (3,4,7), underlying systemic diseases (e.g.
connective tissue disease and vasculitis), toxic inhalants
and drugs that may cause DAD (21). Future studies are
required to evaluate whether certain BALF features are
helpful in establishing the correct diagnosis (7,22,23).
Furthermore, the cellular pro¢le of BALF obtained from
patients su¡ering from other infections including viral
infections, Pneumocystis carinii and Mycobacterium tuber-
culosis should also be evaluated.
To achieve the highest diagnostic e¡ort, BALF analysis
should include appropriate cellular analysis (easily dis-
cernible on MGG stained cytocentrifuged preparations),
additional Perls’ stain for heamosiderin visualization or
iron staining as well as microbiological evaluation. To
date, in an appropriate clinical setting, careful BALF ana-
lysis may contribute to the diagnosis of various ILD,
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X, EAA, drug-induced pneumonitis, di¡use alveolar
damage, eosinophilic pneumonia, BOOP, IPF and sarcoi-
dosis (4,9,24,25).Furthermore, in critically ill patients the
presence of more than one cause of the pulmonary
damage, such as an infection in combination with a drug-
induced pneumonitis, should always be considered and an
extensive review of the clinical record is mandatory to
allow reliable interpretation of BALF analysis results (7).
Asmentioned above, one of the limitations of the pre-
sented computer program is that it only includes the
three most frequent ILDs, i.e. sarcoidosis, IPF and EAA,
and bacterial pneumonia. One should be aware of this
limitation, and, therefore always look carefully at the
BALF cytology.How the diagnostic accuracy of the pro-
gramwould be if other causes of ILD were also included,
such as acute lung injury, bronchiolitis obliterans with
organizing pneumonia (BOOP), or eosinophilic lung dis-
eases as well as viral infections, is unknown at present
and has to be explored.To date, the cellular BALF pro¢le
of a drug-induced hypersensitivity reaction appeared to
be similar to the EAA pro¢le (date not shown). More-
over, a high number of eosinophils (more than 25%) in
BALF makes an eosinophilic lung disease reasonable.
The presence of Reed Sternberg cellsmakes a lymphoma
highly likely (4,24). A milky aspect of the BALF justi¢ed
the suspicion of alveolar proteinosis (4). Furthermore,
the presence of numerous iron-laden macrophages
points to causes of disorders associated with DAD.
Additional iron staining may be helpful to distinguish
between disorders with DAD and other ILD, e.g.
pulmonary vascular disorders such as M.Wegener from
sarcoidosis as both may present with a lymphocytosis in
BALF (26).Moreover, thevalue of BALF cytology¢ndings
for the diagnosis of non-infectious conditions in ICU pa-
tients with suspected pneumoniawas demonstrated (7).
The medical history is extremely important to identify
the possible cause of the pulmonary damage in those
cases. In line with this, one should always interpret
the BALF data in the context of other relevant informa-
tion such as the occupational history of the patient, as
well as other clinical parameters, such as the presence
of precipitines, an elevated serum ACE level and HRCT
features. Therefore, we want to emphasize the impor-
tance of careful assessment of the all cytological BALF
characteristics in order to improve the diagnostic accu-
racy in patients with di¡use lung damage.The computer
model should be used with caution considering the lim-
ited number of diseases included in themodel.However,
the included ILD i.e. sarcoidosis, IPF and EAA cover
about 80^90% of all ILD.
This studyonly focussed on BALF data obtained in the
diagnostic work-up of patients su¡ering fromdi¡use lung
diseases. Although the accuracy of high resolution com-
puted tomography (HRCT) in the di¡erential diagnosis
of these patients has been widely appreciated (1,2,27^29), no HRCT data were included in this model. It would
beveryhelpful if a HRCTscore couldbeused to classify a
certain disorder. However, the attempts made to evalu-
ate the usefulness of HRCT in characterizing disease
weremainly descriptive (27).Moreover, the appearances
on HRCTwere correlatedwith disease activity in ¢bros-
ing alveolitis (29^31), acute farmer’s lung (32), sarcoidosis
(33,34) andWegener’s granulomatosis (26). Itwouldbe of
great interest to develop a valuable diagnostic quantita-
tive HRCT score which discriminates between certain
ILD. Additionally, a prospective study should address
the e¡ect of including this score in a logistic regression
modelupon the diagnostic probabilities of the BALFdata
presented in this study. Includingmore clinical data in the
model may further improve the diagnostic accuracy of
patients su¡ering from di¡use lung diseases.
In conclusion, when applied according to standardized
protocols, and considered in the context of other infor-
mation from conventional ancillary diagnostic tests, such
as aHRCTscan, BAL appears to beuseful in the diagnosis
of di¡use lung diseases.The updated computer program
provides a reliableprediction of the diagnosis of a bacter-
ial pneumonia or one of the threemost frequent intersti-
tial lung diseases, and is thought to improve the
diagnostic power of BALF analysis in conjunction with
other important diagnostic procedures.
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